arthyperАртериальная гипертензия"Arterial’naya Gipertenziya" ("Arterial Hypertension")1607-419X2411-8524Antihypertensive League10.18705/1607-419X-2016-22-5-519-527arthyper-481Research ArticleЛЕКЦИЯLECTUREРаннее повреждение почек у больных артериальной гипертензией: прогностическое значение и подходы к нефропротективной терапииEarly kidney damage in patients with arterial hypertension: prognostic value and approaches to nephroprotective therapyКузьминО. Б.Kuz’minO. B.

доктор медицинских наук, профессор, заведующий кафедрой фармакологии ГБОУ ВПО ОрГМУ Минздрава России Тел.: +7(3532)77–49–66

MD, PhD, DSc, Professor, Head, Department of Pharmacology, Orenburg State Medical University

kuzmin.orgma@mail.ruЖежаВ. В.ZhezhaV. V.

кандидат медицинских наук, доцент кафедры фармакологии ГБОУ ВПО ОрГМУ Минздрава России

MD, PhD, Associate Professor, Department of Pharmacology, Orenburg State Medical University

БелянинВ. В.BelyaninV. V.

кандидат медицинских наук, доцент кафедры фармакологии ГБОУ ВПО ОрГМУ Минздрава России

MD, PhD, Associate Professor, Department of Pharmacology, Orenburg State Medical University

БучневаН. В.BuchnevaN. V.

кандидат медицинских наук, доцент кафедры фармакологии ГБОУ ВПО ОрГМУ Минздрава России

MD, PhD, Associate Professor, Department of Pharmacology, Orenburg State Medical University

Государственное бюджетное образовательное учреждение высшего профессионального образования «Оренбургский государственный медицинский университет» Министерства здравоохранения Российской Федерации, Оренбург, Россия Парковый пр., д. 7, Оренбург, Россия, 460000РоссияOrenburg State Medical University, Orenburg, Russia 7 Park Avenue, Orenburg, Russia, 460000Russian FederationГосударственное бюджетное образовательное учреждение высшего профессионального образования «Оренбургский государственный медицинский университет» Министерства здравоохранения Российской Федерации, Оренбург, РоссияРоссияOrenburg State Medical University, Orenburg, RussiaRussian Federation201629112016225519527Copyright © Кузьмин О.Б., Жежа В.В., Белянин В.В., Бучнева Н.В., 20162016Кузьмин О.Б., Жежа В.В., Белянин В.В., Бучнева Н.В.Kuz’min O.B., Zhezha V.V., Belyanin V.V., Buchneva N.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://htn.almazovcentre.ru/jour/article/view/481

В обзоре представлены результаты клинических исследований, посвященных выяснению у больных артериальной гипертензией прогностического значения альбуминурии А2 (микроальбуминурии), легкой дисфункции почек (скорость клубочковой фильтрации — 60–74 мл/мин/1,73 м 2), биомаркеров повреждения проксимальных канальцев. Также в статье обсуждаются данные, полученные при оценке нефропротективного действия антагониста кальциевых каналов 3‑го поколения лерканидипина и β-адреноблокатора 3‑го поколения карведилола в этой популяции больных.

The review presents the results of clinical studies on the prognostic role of albuminuria A2 (microalbuminuria), mild renal dysfunction (estimated glomerular filtration rate — 60–74 ml/min/1,73 m 2), biomarkers of proximal tubular damage in hypertensive patients. Moreover, we discuss the data on the nephroprotective effects antihypertensive drugs, including calcium channel antagonist 3rd generation lercanidipine and β-blocker 3rd generation carvedilol.

артериальная гипертензияраннее повреждение почеклерканидипинкарведилолarterial hypertensionearly renal damagelercanidipine carvedilolReferencesОщепкова Е. В., Долгушева Ю. А., Жернакова Ю. В., Чазова И. Е., Шальнова С. А., Яровая Е. В. и др. Распространенность нарушения функции почек при артериальной гипертонии (по данным эпидемиологического исследования ЭССЕ-РФ). Системные гипертензии. 2015;12(3):19–24. [Oshchepkova EV, Dolgusheva YuA, Zhernakova YuV, Chasova IE, Shal’nova SA, Iarovaia EB et al. The prevalence of renal dysfunction in arterial hypertension (in the framework of the ESSE-RF study). Sistemnye Gipertenzii = Systemic Hypertension. 2015;12(3):9–24. In Russian].Ощепкова Е. В., Долгушева Ю. А., Жернакова Ю. В., Чазова И. Е., Шальнова С. А., Яровая Е. В. и др. Распространенность нарушения функции почек при артериальной гипертонии (по данным эпидемиологического исследования ЭССЕ-РФ). Системные гипертензии. 2015;12(3):19–24. [Oshchepkova EV, Dolgusheva YuA, Zhernakova YuV, Chasova IE, Shal’nova SA, Iarovaia EB et al. The prevalence of renal dysfunction in arterial hypertension (in the framework of the ESSE-RF study). Sistemnye Gipertenzii = Systemic Hypertension. 2015;12(3):9–24. In Russian].Моисеев В. С., Мухин Н. А., Смирнов А. В., Кобалава Ж. Д., Бобкова И. Н., Виллевальде С. В. и др. Национальные рекомендации. Сердечно-сосудистый риск и хроническая болезнь почек: стратегии кардио-нефропротекции. Клиническая фармакология и терапия. 2014;23(3):4–27. [Moiseev VS, Mukhin NA, Smirnov AV, Kobalava ZhD, Bobkova IN, Villeval’de SV et al. National guidelines. Cardiovascular risk and chronic kidney disease: strategy of cardio-renoprotection. Klinicheskaya Farmacologiya i Terapiya = Clinical Pharmacology and Therapy. 2014;23(3):4–27. In Russian].Моисеев В. С., Мухин Н. А., Смирнов А. В., Кобалава Ж. Д., Бобкова И. Н., Виллевальде С. В. и др. Национальные рекомендации. Сердечно-сосудистый риск и хроническая болезнь почек: стратегии кардио-нефропротекции. Клиническая фармакология и терапия. 2014;23(3):4–27. [Moiseev VS, Mukhin NA, Smirnov AV, Kobalava ZhD, Bobkova IN, Villeval’de SV et al. National guidelines. Cardiovascular risk and chronic kidney disease: strategy of cardio-renoprotection. Klinicheskaya Farmacologiya i Terapiya = Clinical Pharmacology and Therapy. 2014;23(3):4–27. In Russian].Verbeke F, Lindley E, Van Bortel L, Vanholder R, London G, Cochat P et al. A European Renal Best Practice (ERBP) position statement on the kidney disease: Improving Global Outcomes (KDIGO) clinical practice guideline for the management of blood pressure in nondialysis-dependent chronic kidney disease: an endorsement with caveats for real-life application. Nephrol Dial Transplant. 2014;29(3):490–96. doi: 10.1093/ndt/gft321Verbeke F, Lindley E, Van Bortel L, Vanholder R, London G, Cochat P et al. A European Renal Best Practice (ERBP) position statement on the kidney disease: Improving Global Outcomes (KDIGO) clinical practice guideline for the management of blood pressure in nondialysis-dependent chronic kidney disease: an endorsement with caveats for real-life application. Nephrol Dial Transplant. 2014;29(3):490–96. doi: 10.1093/ndt/gft321Pascual JM, Rodilla E, Costa JA, Garsia-Escrich M, Gonzalles C, Redon J. Prognostic value of microalbuminuria during antihypertensive treatment in essential hypertension. Hypertension. 2014;64(6):1228–34. doi: 10.1161/HYPERTENSIONAHA. 114.04273Pascual JM, Rodilla E, Costa JA, Garsia-Escrich M, Gonzalles C, Redon J. Prognostic value of microalbuminuria during antihypertensive treatment in essential hypertension. Hypertension. 2014;64(6):1228–34. doi: 10.1161/HYPERTENSIONAHA. 114.04273Meccariello A, Buono F, Verrengia E, Orefice G, Grieco F, Romeo F et al. Microalbuminuria predicts the recurrence of cardiovascular events in patients with essential hypertension. J Hypertens. 2016;34(4):646–53. doi: 10.1097/HJH.0000000000000846Meccariello A, Buono F, Verrengia E, Orefice G, Grieco F, Romeo F et al. Microalbuminuria predicts the recurrence of cardiovascular events in patients with essential hypertension. J Hypertens. 2016;34(4):646–53. doi: 10.1097/HJH.0000000000000846Leoncini G, Viazzi F, Parodi D, Ratto E, Vettoretti S, Vaccaro V et al. Mild renal dysfunction and cardiovascular risk in hypertensive patients. J Am Soc Nephrol. 2004;15 (Suppl 1): S88‑S90. doi: 10.1097/01.ASN.0000093245.78097.CDLeoncini G, Viazzi F, Parodi D, Ratto E, Vettoretti S, Vaccaro V et al. Mild renal dysfunction and cardiovascular risk in hypertensive patients. J Am Soc Nephrol. 2004;15 (Suppl 1): S88‑S90. doi: 10.1097/01.ASN.0000093245.78097.CDMcCullough PA, Shaw AD, Haase M, Bouchard J, Waikar SS, Siew ED et al. Diagnosis of acute kidney injury using functional and injury biomarkers: workgroup statements from the tenth Acute Diagnosis Quality Initiative Consensus Conference. Contrib Nephrol. 2013;182:13–29. doi: 10.1159/000349963McCullough PA, Shaw AD, Haase M, Bouchard J, Waikar SS, Siew ED et al. Diagnosis of acute kidney injury using functional and injury biomarkers: workgroup statements from the tenth Acute Diagnosis Quality Initiative Consensus Conference. Contrib Nephrol. 2013;182:13–29. doi: 10.1159/000349963Кузьмин О. Б., Белянин В. В., Жежа В. В., Сердюк С. В. Диагностическая и прогностическая ценность новых биомаркеров повреждения почек у больных острой и хронической сердечной недостаточностью. Журнал Сердечная недостаточность. 2015;16(1):57–64. [Kuz’min OB, Belyanin VV, Zhezha VV, Serdyuk SV. Diagnostic and prognostic value of novel biomarkers of renal damage in acute chronic heart failure. Serdechnaya Nedostatochnost’ = Heart Failure. 2015;16(1):57–64. In Russian].Кузьмин О. Б., Белянин В. В., Жежа В. В., Сердюк С. В. Диагностическая и прогностическая ценность новых биомаркеров повреждения почек у больных острой и хронической сердечной недостаточностью. Журнал Сердечная недостаточность. 2015;16(1):57–64. [Kuz’min OB, Belyanin VV, Zhezha VV, Serdyuk SV. Diagnostic and prognostic value of novel biomarkers of renal damage in acute chronic heart failure. Serdechnaya Nedostatochnost’ = Heart Failure. 2015;16(1):57–64. In Russian].Кузьмин О. Б., Пугаева М. О., Чуб С. В. Легкая дисфункция почек у больных эссенциальной гипертонией: клинические проявления и лекарственная терапия. Нефрология. 2004;8 (3):15–21. [Kuz’min OB, Pugaeva MO, Chub SV. Mild renal dysfunction in patients with essential hypertension: clinical signs and drug therapy. Nefrologiya = Nephrology. 2004;8(3):15–21. In Russian].Кузьмин О. Б., Пугаева М. О., Чуб С. В. Легкая дисфункция почек у больных эссенциальной гипертонией: клинические проявления и лекарственная терапия. Нефрология. 2004;8 (3):15–21. [Kuz’min OB, Pugaeva MO, Chub SV. Mild renal dysfunction in patients with essential hypertension: clinical signs and drug therapy. Nefrologiya = Nephrology. 2004;8(3):15–21. In Russian].Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2013;3 (Suppl l):1–150.Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2013;3 (Suppl l):1–150.Кобалава Ж. Д., Виллевальде С. В., Ефремовцева М. А. Самостоятельное диагностическое значение микро- альбуминурии и расчетной скорости клубочковой фильтрации у больных с артериальной гипертензией для выявления субклинического поражения почек. Кардиология. 2010;50(4):12–17. [Kobalava ZhD, Villeval’de SV, Efremovtseva MA. Independent diagnostic value of microalbuminuria and calculated glomerular filtration rate in patients with arterial hypertension for detection of subclinical renal involvement. Kardiologiia. 2010;50(4):12–17. In Russian].Кобалава Ж. Д., Виллевальде С. В., Ефремовцева М. А. Самостоятельное диагностическое значение микро- альбуминурии и расчетной скорости клубочковой фильтрации у больных с артериальной гипертензией для выявления субклинического поражения почек. Кардиология. 2010;50(4):12–17. [Kobalava ZhD, Villeval’de SV, Efremovtseva MA. Independent diagnostic value of microalbuminuria and calculated glomerular filtration rate in patients with arterial hypertension for detection of subclinical renal involvement. Kardiologiia. 2010;50(4):12–17. In Russian].Ceralosa G, Mule G, Cottone S, Nardi T, Cusimano P. Hypertension, microalbuminuria and renal dysfunction: the Renal Dysfunction in Hypertension (REDHY) study. J Nephrol. 2008;21(3):368–373.Ceralosa G, Mule G, Cottone S, Nardi T, Cusimano P. Hypertension, microalbuminuria and renal dysfunction: the Renal Dysfunction in Hypertension (REDHY) study. J Nephrol. 2008;21(3):368–373.de la Sierra A, Eqocheaqa MI, Aqilera MT. Prevalence and clinical characteristics of albuminuria in the Spanish hypertensive population. Med Clin. 2008;130(6):201–205. doi: 10.1157/13116170de la Sierra A, Eqocheaqa MI, Aqilera MT. Prevalence and clinical characteristics of albuminuria in the Spanish hypertensive population. Med Clin. 2008;130(6):201–205. doi: 10.1157/13116170Чазова И. Е., Ратова Л. Г., Амбатьелло Л. Г. Значение микроальбуминурии у больных артериальной гипертензией и возможности ее лечения. Системные гипертензии. 2011;8 (2):17–21. [Chazova IE, Ratova LG, Ambat’ello LG. The value of microalbuminuria in hypertensive patients and the possibility of treatment. Sistemnye Gipertenzii = Systemic Hypertension. 2011;8 (2):17–21. In Russian].Чазова И. Е., Ратова Л. Г., Амбатьелло Л. Г. Значение микроальбуминурии у больных артериальной гипертензией и возможности ее лечения. Системные гипертензии. 2011;8 (2):17–21. [Chazova IE, Ratova LG, Ambat’ello LG. The value of microalbuminuria in hypertensive patients and the possibility of treatment. Sistemnye Gipertenzii = Systemic Hypertension. 2011;8 (2):17–21. In Russian].Klausen KP, Scharing H, Jensen O, Jensen JS. New definition of microalbuminuria in hypertensive subjects: association with coronary heart disease. Hypertension. 2005;46(1):33–37. doi: 10.1161/01.HYP.0000169153.78459.50Klausen KP, Scharing H, Jensen O, Jensen JS. New definition of microalbuminuria in hypertensive subjects: association with coronary heart disease. Hypertension. 2005;46(1):33–37. doi: 10.1161/01.HYP.0000169153.78459.50Viazzi F, Leonchini G, Conti N, Tomolillo C, Giachero G, Vercelli M et al. Microalbuminuria as a predictor chronic renal insufficiency in patients without diabetes and with hypertension. CJASN. 2010;5(6):1099–1106. doi: 10.2215/CJN.07271009Viazzi F, Leonchini G, Conti N, Tomolillo C, Giachero G, Vercelli M et al. Microalbuminuria as a predictor chronic renal insufficiency in patients without diabetes and with hypertension. CJASN. 2010;5(6):1099–1106. doi: 10.2215/CJN.07271009Ibsen H, Watchtell K, Olsen MH, Borch-Johnsen K, Lindholm LH, Mogensen C et al. Albuminuria and cardiovascular risk in hypertensive patients with ventricular hypertrophy: the LIFE Study. Kidney Int Suppl. 2004;92: S56–58. doi: http://dx.doi.org/10.1111/j.1523–1755.2004.09214.xIbsen H, Watchtell K, Olsen MH, Borch-Johnsen K, Lindholm LH, Mogensen C et al. Albuminuria and cardiovascular risk in hypertensive patients with ventricular hypertrophy: the LIFE Study. Kidney Int Suppl. 2004;92: S56–58. doi: http://dx.doi.org/10.1111/j.1523–1755.2004.09214.xКузьмин О. Б., Белянин В. В., Жежа В. В. Легкая дисфункция почек у больных сердечной недостаточностью: доклинические признаки и их прогностическое значение. Журнал Сердечная недостаточность. 2014;15(2):126–131. [Kuz’min OB, Belyanin VV, Zhezha VV. Mild renal dysfunction in patients with heart failure: preclinical signs and their prognostic value. Zhurnal Serdechnaya nedostatochnost’ = Journal Heart Failure. 2014;15(2):126–131. In Russian].Кузьмин О. Б., Белянин В. В., Жежа В. В. Легкая дисфункция почек у больных сердечной недостаточностью: доклинические признаки и их прогностическое значение. Журнал Сердечная недостаточность. 2014;15(2):126–131. [Kuz’min OB, Belyanin VV, Zhezha VV. Mild renal dysfunction in patients with heart failure: preclinical signs and their prognostic value. Zhurnal Serdechnaya nedostatochnost’ = Journal Heart Failure. 2014;15(2):126–131. In Russian].Roy SK, Cespedes A, Li D, Choi TV, Budoff VJ. Mild and moderate predialisys chronic kidney disease is associated with increased coronary artery calcium. Vasc Health Risk Manag. 2011;7:19–24. doi: http://dx.doi.org/10.2147/VHRM.S24536Roy SK, Cespedes A, Li D, Choi TV, Budoff VJ. Mild and moderate predialisys chronic kidney disease is associated with increased coronary artery calcium. Vasc Health Risk Manag. 2011;7:19–24. doi: http://dx.doi.org/10.2147/VHRM.S24536Zhang JH, Xu Y, Chen XH, Wu MZ, Cheng ZP, Chen B. The predictive value of mild renal insufficiency on the prognosis of patients with acute coronary syndrome. Zhonghua Nei Ke Za Zhi. 2013;52(12):1033–1036.Zhang JH, Xu Y, Chen XH, Wu MZ, Cheng ZP, Chen B. The predictive value of mild renal insufficiency on the prognosis of patients with acute coronary syndrome. Zhonghua Nei Ke Za Zhi. 2013;52(12):1033–1036.Fiseha T, Tamir Z. Urinary markers of tubular injury in early diabetic nephropathy. Int J Nephrol. 2016;2016:4647685. doi: 10.1155/2016/4647685Fiseha T, Tamir Z. Urinary markers of tubular injury in early diabetic nephropathy. Int J Nephrol. 2016;2016:4647685. doi: 10.1155/2016/4647685Alderman MH, Meicher L, Drayer DE, Reidenbery MM. Increased excretion of urinary N‑acetyl-beta-glucosaminidase in essential hypertension and its decline with antihypertensive therapy. N Engl J Med. 1983;309(20):1213–7. doi: 10.1056/NEJM198311173092004Alderman MH, Meicher L, Drayer DE, Reidenbery MM. Increased excretion of urinary N‑acetyl-beta-glucosaminidase in essential hypertension and its decline with antihypertensive therapy. N Engl J Med. 1983;309(20):1213–7. doi: 10.1056/NEJM198311173092004Maldonado-Martin A, Rueda-Illescas D, Extremere B, Soriano-Corracosa L, Alonso- Morales F, Garsia-Perez F et al. Endothelins and markers of renal damage in recently diagnosed hypertensive patients. J Clin Hypertens (Greenwich). 2002;4 (5):346–354. doi: 10.1111/j.1524–6175.2002.00489.xMaldonado-Martin A, Rueda-Illescas D, Extremere B, Soriano-Corracosa L, Alonso- Morales F, Garsia-Perez F et al. Endothelins and markers of renal damage in recently diagnosed hypertensive patients. J Clin Hypertens (Greenwich). 2002;4 (5):346–354. doi: 10.1111/j.1524–6175.2002.00489.xXu X, Fang Y, Ji J. Value of urinary kidney biomarkers for estimation of renal impairment in elderly Chinese with essential hypertension. J Clin Lad Anal. 2008;22(1):86–90. doi: 10.1002/jcla.20220Xu X, Fang Y, Ji J. Value of urinary kidney biomarkers for estimation of renal impairment in elderly Chinese with essential hypertension. J Clin Lad Anal. 2008;22(1):86–90. doi: 10.1002/jcla.20220Lisowska-Myiak B, Krych A, Kolodziejczyk A, Pacheko J, Gaciong Z. Urinary proteins, N‑acetyl-β-D‑glucosaminidase and estimated glomerular filtration rate in hypertensive patients with normoalbuminuria and microalbuminuria. Nephrology (Carlton). 2011;16(4):403–9. doi: 10.1111/j.1440–1797.2011.01444.xLisowska-Myiak B, Krych A, Kolodziejczyk A, Pacheko J, Gaciong Z. Urinary proteins, N‑acetyl-β-D‑glucosaminidase and estimated glomerular filtration rate in hypertensive patients with normoalbuminuria and microalbuminuria. Nephrology (Carlton). 2011;16(4):403–9. doi: 10.1111/j.1440–1797.2011.01444.xBakris GL, Weir MR, Secic M. Campbell B, Weis-McNulty A. Differential effects of calcium antagonists subclasses on markers of nephropathy progression. Kidney Int. 2004;65(6):1991– 2002. doi: http://dx.doi.org/10.1111/j.1523–1755.2004.00620.xBakris GL, Weir MR, Secic M. Campbell B, Weis-McNulty A. Differential effects of calcium antagonists subclasses on markers of nephropathy progression. Kidney Int. 2004;65(6):1991– 2002. doi: http://dx.doi.org/10.1111/j.1523–1755.2004.00620.xNakamura T, Inone T, Suzuki T, Kawagoe Y, Ueda Y, Koide H et al. Comparison of renal and vascular protective effects between telmisartan and amlodipine in hypertensive patients with chronic kidney disease with mild renal insufficiency. Hypertension Res. 2008;31(5):841–850. doi: 10.1291/hypres.31.841Nakamura T, Inone T, Suzuki T, Kawagoe Y, Ueda Y, Koide H et al. Comparison of renal and vascular protective effects between telmisartan and amlodipine in hypertensive patients with chronic kidney disease with mild renal insufficiency. Hypertension Res. 2008;31(5):841–850. doi: 10.1291/hypres.31.841Hayashi M, Ushida S, Kawamura T, Kawahara M, Nangaku M, Iino Y et al. Prospective randomized study of tolerability and efficacy of combination therapy for hypertensive chronic kidney disease: results of the PROTECT-CKD study. Clin Exp Nephrol. 2015;19(5):925–32. doi: 10.1007/s10157–015–1091–5Hayashi M, Ushida S, Kawamura T, Kawahara M, Nangaku M, Iino Y et al. Prospective randomized study of tolerability and efficacy of combination therapy for hypertensive chronic kidney disease: results of the PROTECT-CKD study. Clin Exp Nephrol. 2015;19(5):925–32. doi: 10.1007/s10157–015–1091–5Sabbatini M, Leonardi A, Testa R, Vitaioli L, Amenta F. Effect of calcium antagonists on glomerular arterioles in spontaneously hypertensive rats. Hypertension. 2000;35(3):775–79. doi: 10.1161/01.HYP.35.3.775Sabbatini M, Leonardi A, Testa R, Vitaioli L, Amenta F. Effect of calcium antagonists on glomerular arterioles in spontaneously hypertensive rats. Hypertension. 2000;35(3):775–79. doi: 10.1161/01.HYP.35.3.775Sabbatini M, Vitaioli L, Baldoni E, Amenta F. Nephroprotective effect of treatment with calcium channel blockers in spontaneously hypertensive rats. J Pharmacol Exp Ther. 2000;294 (3):948–954.Sabbatini M, Vitaioli L, Baldoni E, Amenta F. Nephroprotective effect of treatment with calcium channel blockers in spontaneously hypertensive rats. J Pharmacol Exp Ther. 2000;294 (3):948–954.Cominacini L, Fratta-Pasini A, Garbin U, Pastorino AM, Davoli A, Nava C et al. Antioxidant activity of different dihydropyridines. Biochem Biophys Res Commun. 2003;302(4):679–684. doi: 10.1016/S0006–291X (03)00158‑XCominacini L, Fratta-Pasini A, Garbin U, Pastorino AM, Davoli A, Nava C et al. Antioxidant activity of different dihydropyridines. Biochem Biophys Res Commun. 2003;302(4):679–684. doi: 10.1016/S0006–291X (03)00158‑XVasigar P, Batmanabane M. Anti-inflammatory activity of calcium channel blocker lercanidipine hydrochloride. J Pharmacol Pharmacother. 2013;4(4):238–242. doi: 10.4103/0976–500X.119707Vasigar P, Batmanabane M. Anti-inflammatory activity of calcium channel blocker lercanidipine hydrochloride. J Pharmacol Pharmacother. 2013;4(4):238–242. doi: 10.4103/0976–500X.119707Yeh JL, Hsu JH, Liang JC, Chen IJ, Liou SF. Lercanidipine and labedipinediol-A attenuate lipolysaccaride/interferon- γ-induced inflammation in rat vascular smooth muscle cells through inhibition HMGB1 release and MMP‑2,9 activities. Atherosclerosis. 2013;226(2):364–372. doi: 10.1016/j.atherosclerosis. 2012.12.005Yeh JL, Hsu JH, Liang JC, Chen IJ, Liou SF. Lercanidipine and labedipinediol-A attenuate lipolysaccaride/interferon- γ-induced inflammation in rat vascular smooth muscle cells through inhibition HMGB1 release and MMP‑2,9 activities. Atherosclerosis. 2013;226(2):364–372. doi: 10.1016/j.atherosclerosis. 2012.12.005Fogari R, Mugellini A, Zoppi A, Corradi L, Rinaldi A, Derosa G et al. Differential effect of lercanidipine and nifedipine GTTS on plasma norepinephrine in chronic treatment of hypertension. Am J Hypertens. 2003;16(7):596–99. doi: 10.1016/S0895–7061 (03)00901–4Fogari R, Mugellini A, Zoppi A, Corradi L, Rinaldi A, Derosa G et al. Differential effect of lercanidipine and nifedipine GTTS on plasma norepinephrine in chronic treatment of hypertension. Am J Hypertens. 2003;16(7):596–99. doi: 10.1016/S0895–7061 (03)00901–4Seravalle J, Brambilla J, Pizzalla DP, Casati A, Riva M, Cuspidi C et al. Differential effects of enalapril-felodipine versus enalapril-lercanidipine combination drug treatment on sympathetic nerve traffic and metabolic profile in obesity-related hypertension. J Am Soc Hypertens. 2016;10(3):244–251. doi: 10.1016/j.jash.2016.01.006Seravalle J, Brambilla J, Pizzalla DP, Casati A, Riva M, Cuspidi C et al. Differential effects of enalapril-felodipine versus enalapril-lercanidipine combination drug treatment on sympathetic nerve traffic and metabolic profile in obesity-related hypertension. J Am Soc Hypertens. 2016;10(3):244–251. doi: 10.1016/j.jash.2016.01.006Dalla-Vestra M, Pozza G, Mosca A, Grazioli V, Lapollo A, Fioretto P et al. Effect of lercanidipine compared with ramipril on albumin excretion rate in hypertensive type 2 diabetic patients with microalbuminuria: DIAL study (diabetes, ipertensione, albuminuria, lercanidipine). Diabetes Nutr Metab. 2004;17(5):259–266.Dalla-Vestra M, Pozza G, Mosca A, Grazioli V, Lapollo A, Fioretto P et al. Effect of lercanidipine compared with ramipril on albumin excretion rate in hypertensive type 2 diabetic patients with microalbuminuria: DIAL study (diabetes, ipertensione, albuminuria, lercanidipine). Diabetes Nutr Metab. 2004;17(5):259–266.Robles NR, Ocon J, Gomez CF, Manjon M, Pastor L, Herrera J et al. Lercanidipine in patients with chronic renal failure: the ZAFRA study. Ren Fail. 2005;27(1):73–80. doi: 10.1081/JDI‑42801Robles NR, Ocon J, Gomez CF, Manjon M, Pastor L, Herrera J et al. Lercanidipine in patients with chronic renal failure: the ZAFRA study. Ren Fail. 2005;27(1):73–80. doi: 10.1081/JDI‑42801Robles NR, Romero B, de Vinuesa EG, Sanchez-Casado E, Cubero JJ. Treatment of proteinuria with lercanidipine associated with renin-angiotensin axis-blocking drugs. Ren Fail. 2010;32 (2):192–97. doi: 10.3109/08860220903541135Robles NR, Romero B, de Vinuesa EG, Sanchez-Casado E, Cubero JJ. Treatment of proteinuria with lercanidipine associated with renin-angiotensin axis-blocking drugs. Ren Fail. 2010;32 (2):192–97. doi: 10.3109/08860220903541135Кузьмин О. Б., Жежа В. В., Ландарь Л. Н. Нефропротективные свойства дигидропиридиновых блокаторов Са2+-каналов. Обзоры по клинической фармакологии и лекарственной терапии. 2010;8(1):6–12. [Kuz’min OB, Zhezha VV, Landar LN. Renoprotective properties of dihydropyridine Са2+-channel blockers. Obzory po Klinicheskoy Farmakologii i Lekarstvennoy Terapii = Reviews of Clinical Pharmacology and Drug Therapy. 2010;8(1):6–12. In Russian].Кузьмин О. Б., Жежа В. В., Ландарь Л. Н. Нефропротективные свойства дигидропиридиновых блокаторов Са2+-каналов. Обзоры по клинической фармакологии и лекарственной терапии. 2010;8(1):6–12. [Kuz’min OB, Zhezha VV, Landar LN. Renoprotective properties of dihydropyridine Са2+-channel blockers. Obzory po Klinicheskoy Farmakologii i Lekarstvennoy Terapii = Reviews of Clinical Pharmacology and Drug Therapy. 2010;8(1):6–12. In Russian].Tamcharoen N, Susantitaphong P, Wongrakpanich S, Chongsathidkiet P, Tantrachoti P, Pitukweerakul S et al. Effect of Nand T‑type calcium channel blockers on proteinuria, blood pressure and kidney function in hypertensive patients: a meta-analysis. Hypertens Res. 2015;38(12):847–855. doi: 10.1038/hr.2015.69Tamcharoen N, Susantitaphong P, Wongrakpanich S, Chongsathidkiet P, Tantrachoti P, Pitukweerakul S et al. Effect of Nand T‑type calcium channel blockers on proteinuria, blood pressure and kidney function in hypertensive patients: a meta-analysis. Hypertens Res. 2015;38(12):847–855. doi: 10.1038/hr.2015.69Кузьмин О. Б., Белянин В. В., Жежа В. В. Нефропротекторные свойства бета- адреноблокаторов третьего поколения. Экспериментальная и клиническая фармакология. 2014;77 (3):40–43. [Kuz’min OB, Belyanin VV, Zhezha VV. Renoprotective properties of beta-blockers of third generation. Eksperimental’naya i Klinicheskaya Farmacologiya = Experimental and Clinical Pharmacology. 2014;77(3):40–43. In Russian].Кузьмин О. Б., Белянин В. В., Жежа В. В. Нефропротекторные свойства бета- адреноблокаторов третьего поколения. Экспериментальная и клиническая фармакология. 2014;77 (3):40–43. [Kuz’min OB, Belyanin VV, Zhezha VV. Renoprotective properties of beta-blockers of third generation. Eksperimental’naya i Klinicheskaya Farmacologiya = Experimental and Clinical Pharmacology. 2014;77(3):40–43. In Russian].Gao G, Llambi HG, Ottaviano G, Muller A, Milei J. Carvedilol protects the peritubular capillaries and kidney structure in spontaneously hypertensive rats. Int J Cardiol. 2015;181:415–16. doi: 10.1016/j.ijcard.2014.12.049Gao G, Llambi HG, Ottaviano G, Muller A, Milei J. Carvedilol protects the peritubular capillaries and kidney structure in spontaneously hypertensive rats. Int J Cardiol. 2015;181:415–16. doi: 10.1016/j.ijcard.2014.12.049Brooks DP, Short BJ, Cyronak MJ, Contino LC, DiCristo M, Wang YX et al. Comparison between carvedilol and captopril in rats with partial oblation-induced chronic renal failure. Br J Pharmacol. 1993;109(2):581–86.Brooks DP, Short BJ, Cyronak MJ, Contino LC, DiCristo M, Wang YX et al. Comparison between carvedilol and captopril in rats with partial oblation-induced chronic renal failure. Br J Pharmacol. 1993;109(2):581–86.Mory MA, Ibrahim SA, Amin EF, Kamel MY, Abdelwahab SA, Hassan MK. Carvedilol ameliorates early diabetic nephropathy in streptozotocin-induced diabetic rats. Biomed Res Int. 2014;2014:105214. doi: 10.1155/2014/105214Mory MA, Ibrahim SA, Amin EF, Kamel MY, Abdelwahab SA, Hassan MK. Carvedilol ameliorates early diabetic nephropathy in streptozotocin-induced diabetic rats. Biomed Res Int. 2014;2014:105214. doi: 10.1155/2014/105214Marchi F, Ciriello G. Efficacy of carvedilol in mild to moderate essential hypertension and effects on microalbuminuria: a multicentre randomized, open-label, controlled study versus atenolol. Adv Ther. 1995;12(4):212–21.Marchi F, Ciriello G. Efficacy of carvedilol in mild to moderate essential hypertension and effects on microalbuminuria: a multicentre randomized, open-label, controlled study versus atenolol. Adv Ther. 1995;12(4):212–21.Fassbinder W, Quarder O, Waltz A. Treatment with carvedilol is associated with a significant reduction of microalbuminuria: a multicentre randomized study. Int J Clin Practic. 1999;53(7):519–22.Fassbinder W, Quarder O, Waltz A. Treatment with carvedilol is associated with a significant reduction of microalbuminuria: a multicentre randomized study. Int J Clin Practic. 1999;53(7):519–22.Bakris GL, Fonseca V, Katholi RE, McGill JB, Messerti F, Phillips RA et al. Differential effects of beta-blockers on albuminuria in patients with type 2 diabetes. Hypertension. 2005;46 (6):1309–15. doi: 10.1161/01.HYP.0000190585.54734.48Bakris GL, Fonseca V, Katholi RE, McGill JB, Messerti F, Phillips RA et al. Differential effects of beta-blockers on albuminuria in patients with type 2 diabetes. Hypertension. 2005;46 (6):1309–15. doi: 10.1161/01.HYP.0000190585.54734.48

The authors declare that there are no conflicts of interest present.